NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH JURISDICTION. NEITHER THIS ANNOUNC

FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM ANY JURISDICTION IN WHICH THE

SAME WOULD BE A VIOLATION OF THE LAWS OF SUCH JURISDICTION. NEITHER THIS ANNOUNCEMENT, NOR ANYTHING CONTAINED HEREIN, SHALL FORM THE

BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY OFFER OR COMMITMENT WHATSOEVER IN ANY JURISDICTION.

OF GENERAL MEETING AND PUBLICATION OF CIRCULAR

and New York, NY, 5 April 2023 - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"),

an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet

need in this multi-billion-dollar market, announces that, further to its announcement on 4 April 2023, it has today posted a circular

(the "Circular") to shareholders which contains further details regarding the proposed cancellation of its ordinary

shares of no par value each ("Ordinary Shares") from listing on the standard segment of the Official List of the Financial

Conduct Authority and trading on the main market for listed securities of London Stock Exchange plc and associated timetable, together

with proposals to be put to shareholders at a general meeting of the Company to be held at the offices of Orrick, Herrington & Sutcliffe

(UK) LLP at 107 Cheapside, London EC2V 6DN, United Kingdom at 12.00 midday on 3 May 2023 (the "General Meeting"),

including, inter alia, to consolidate every 65 existing Ordinary Shares into one new ordinary share of no par value (thereby matching

its current American Depositary Share ratio). The Circular will shortly be posted to the Company's website at: https://okyopharma.com/investors/corporate-governance/corporate-documents/

Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the

Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange

plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For

further information, please visit www.okyopharma.com.

is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells

of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce

a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing

activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of

the lipid anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.